regardless of positive clinical data, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is facing considerable difficulty from pharmacy benefit managers. These companies are frequently creating obstacles to coverage, like significant price criteria and PA that restrict user availability. Analysts sugges… Read More